Search Results - inflammatory+bowel+disease+(ibd)

4 Results Sort By:
Treatment of Irritable Bowel Syndrome with Molybdenum
Unmet NeedIrritable Bowel Syndrome is a chronic and incurable gastrointestinal disorder that affects 3-20% of Americans depending on certain sociocultural and comorbid factors. A poorly understood condition, current treatments consist of antispasmodics, antidiarrheals, and dietary restrictions. Unable to alleviate all its symptoms, researchers are in...
Published: 3/13/2025   |   Inventor(s): Pankaj Pasricha, Lian Sheng Liu, Qian Li, Alfred Spormann
Keywords(s): Disease Indication, Gastrointestinal Disorders, Inflammatory Bowel Disease (IBD), Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Gastroenterology > Irritable Bowel Disease
Inflammatory Bowel Disease (IBD): New Cytokine Biomarkers
C10931: Markers for Diagnosis and/or Prognosis of Irritable Bowel Disease and Syndrome Value Proposition: - The identified markers may be combined to optimize sensitivity and specificity. - These markers may be used in ELISA or Chip format. - Markers have been validated using colonic tissue biopsy samples. - Predicate technology and CPT codes already...
Published: 3/13/2025   |   Inventor(s): Michael Centola, Nicholas Knowlton, Xuhang Li, Philip Alex
Keywords(s): Biomarker, Chronic Inflammatory Diseases, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, Gastrointestinal Disorders, In Vitro Diagnostics, Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD)
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease, Clinical and Disease Specializations > Inflammation > Chronic Inflammatory Diseases, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Inflammation
Identification of Novel Serological Biomarkers for Inflammatory Bowel Disease Using E.coli Proteome Chip
C10584: Novel Diagnostics for IBDNovelty: This technology involves use of novel E. coli proteome chip to diagnose, monitor and select appropriate treatments for patients suffering from inflammatory bowel disease (IBD).Value Proposition: Current diagnostic methods for inflammatory bowel disease are invasive and patients find these tests unpleasant. The...
Published: 3/13/2025   |   Inventor(s): Heng Zhu, Xuhang Li
Keywords(s): Biomarker, Chronic Inflammatory Diseases, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, Gastrointestinal Disorders, In Vitro Diagnostics, Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD), Inflammatory Disorders
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease, Clinical and Disease Specializations > Inflammation > Chronic Inflammatory Diseases, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Inflammation
PNU-120596 and 3-(2,4-dimethoxybenzylidene) Anabaseine (GTS-21) (both nAchRa7 agonists) and Methyllycaconitine (anAchRa7 antagonist), are Highly Effective Drugs in Therapy of Ulcerative Colitis (UC) and Crohn's Disease (CD)
C10382: Breakthrough Therapeutic for Inflammatory Bowel Diseases (IBD)Novelty: This technology identifies a nicotinic acetylcholine receptor isoform (nAChR7) that has a prevalent role in affecting Inflammatory Bowel Disease (IBD), as well as several agonist/antagonists to nAChR7, that are highly effective in both the prevention and therapy of ulcerative...
Published: 3/13/2025   |   Inventor(s): Philip Alex, Michael Centola, Xuhang Li
Keywords(s): Chronic Inflammatory Diseases, Combination, Crohn's disease, Crohn's Disease, Disease Indication, Gastrointestinal Disorders, Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD), Natural compounds, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Ulcerative Colitis, Ulcerative Colitis (UC)
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology > Crohn's Disease, Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease, Clinical and Disease Specializations > Gastroenterology > Ulcerative Colitis, Clinical and Disease Specializations > Inflammation > Chronic Inflammatory Diseases, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Inflammation, Technology Classifications > Therapeutic Modalities
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum